SuperworthAbbott Laboratories ABT
Medical - Devices, Healthcare
$98.73
+0.58%
- Market cap
- $170.8B
- PE
- 31.8×
- 10y median 36.2×
- Forward PE
- Price to sales
- 3.7×
- EV/EBIT
- 27.0×
- Revenue, 12 months
- $46.6B
- +8% on a year ago
- Net margin
- 11.6%
- Free cash flow yield
- 4.6%
Abbott Laboratories trades at 31.8× trailing earnings, cheaper than 70% of the last ten years. Revenue was $46.6B over the last twelve months, up 8% on a year earlier with a 12% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.2B | $10B | $10.4B | $10.6B | $11B+7% | $10.4B+4% | $11.1B+7% | $11.4B+7% | $11.5B+4% | $11.2B+8% | $12.6B+13% | |
| Cost of revenue | $4.6B | $4.5B | $4.6B | $4.7B | $4.9B+9% | $4.5B+0% | $4.9B+6% | $5.1B+8% | $4.9B−0% | $4.9B+9% | $5.3B+10% |
| Gross profit | $5.7B | $5.5B | $5.8B | $5.9B | $6B+6% | $5.9B+7% | $6.3B+9% | $6.3B+6% | $6.5B+8% | $6.3B+7% | $7.3B+16% |
| R&D | $700M | $684M | $698M | $713M | $749M+7% | $716M+5% | $725M+4% | $766M+7% | $735M−2% | $767M+7% | $892M+23% |
| SG&A | $2.7B | $3B | $2.9B | $2.9B | $2.9B+7% | $3.1B+3% | $3.1B+5% | $3.1B+5% | $3.1B+8% | $3.7B+22% | $4B+30% |
| $1.8B | $1.4B | $1.7B | $1.9B | $1.9B+7% | $1.7B+22% | $2.1B+23% | $2.1B+11% | $2.3B+18% | $1.3B−21% | $1.7B−18% | |
| Interest expense | $235M | $117M | $168M | $166M | $152M−35% | $134M+15% | $121M−28% | $44M−74% | $120M−21% | $174M+30% | $299M+147% |
| Pre-tax income | $1.8B | $1.4B | $1.6B | $1.9B | $2B+13% | $1.8B+24% | $2.1B+34% | $2.2B+12% | $2.4B+16% | $1.4B−19% | $1.5B−29% |
| $201M | $211M | $305M | $294M | −$7.2B | $453M+115% | $371M+22% | $536M+82% | $582M | $372M−18% | $596M+61% | |
| Net income | $1.6B | $1.2B | $1.3B | $1.6B | $9.2B+479% | $1.3B+8% | $1.8B+37% | $1.6B−0% | $1.8B−81% | $1.1B−19% | $928M−48% |
| $0.91 | $0.70 | $0.74 | $0.94 | $5.27+479% | $0.76+9% | $1.01+37% | $0.94+0% | $1.02−81% | $0.61−20% | $0.53−48% | |
| 1.7B | 1.7B | 1.8B | 1.7B | 1.7B−0% | 1.7B−0% | 1.8B+0% | 1.7B+0% | 1.7B+0% | 1.7B+0% | 1.7B−0% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Devices within ten times Abbott Laboratories's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ABTAbbott Laboratories | $170.8B | 31.8× | 36.2× | 3.7× | +8% | 11.6% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| BSXBoston Scientific Corporation | $60.3B | 16.8× | 66.3× | 2.9× | +14% | 17.5% | |
| EWEdwards Lifesciences Corporation | $49.4B | 49.3× | 40.5× | 7.6× | +15% | 15.4% | |
| DXCMDexCom, Inc. | $31.8B | 33.3× | 142× | 6.4× | +16% | 20.1% | |
| GEHCGE HealthCare Technologies Inc. | $29.2B | 18.7× | 19.9× | 1.4× | +7% | 9.3% | |
| Peer median | $54.9B | 24.8× | 40.8× | 3.5× | +12% | 14.9% |
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .